GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » SEEGENE Inc (XKRX:096530) » Definitions » EV-to-EBIT

SEEGENE (XKRX:096530) EV-to-EBIT : 11.87 (As of May. 26, 2024)


View and export this data going back to 2010. Start your Free Trial

What is SEEGENE EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, SEEGENE's Enterprise Value is ₩605,769 Mil. SEEGENE's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was ₩51,038 Mil. Therefore, SEEGENE's EV-to-EBIT for today is 11.87.

The historical rank and industry rank for SEEGENE's EV-to-EBIT or its related term are showing as below:

XKRX:096530' s EV-to-EBIT Range Over the Past 10 Years
Min: -609.52   Med: 64.25   Max: 216.66
Current: 11.87

During the past 13 years, the highest EV-to-EBIT of SEEGENE was 216.66. The lowest was -609.52. And the median was 64.25.

XKRX:096530's EV-to-EBIT is ranked worse than
53.29% of 426 companies
in the Biotechnology industry
Industry Median: 10.295 vs XKRX:096530: 11.87

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. SEEGENE's Enterprise Value for the quarter that ended in Mar. 2024 was ₩1,112,242 Mil. SEEGENE's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was ₩51,038 Mil. SEEGENE's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was 4.59%.


SEEGENE EV-to-EBIT Historical Data

The historical data trend for SEEGENE's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SEEGENE EV-to-EBIT Chart

SEEGENE Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 26.46 7.16 4.09 3.96 157.36

SEEGENE Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 49.62 -39.64 -490.12 157.36 21.79

Competitive Comparison of SEEGENE's EV-to-EBIT

For the Biotechnology subindustry, SEEGENE's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


SEEGENE's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, SEEGENE's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where SEEGENE's EV-to-EBIT falls into.



SEEGENE EV-to-EBIT Calculation

SEEGENE's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=605769.405/51038.392
=11.87

SEEGENE's current Enterprise Value is ₩605,769 Mil.
SEEGENE's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩51,038 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


SEEGENE  (XKRX:096530) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

SEEGENE's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Mar. 2024 ) =EBIT / Enterprise Value (Q: Mar. 2024 )
=51038.392/1112241.86
=4.59 %

SEEGENE's Enterprise Value for the quarter that ended in Mar. 2024 was ₩1,112,242 Mil.
SEEGENE's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩51,038 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


SEEGENE EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of SEEGENE's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


SEEGENE (XKRX:096530) Business Description

Traded in Other Exchanges
N/A
Address
Taewon Building 65-5 Bangyi-Dong, Songpa-gu, Seoul, KOR, 138-050
SEEGENE Inc is engaged in the healthcare sector. The Korean firm specializes in developing upgraded technology for accurate diagnosis of various diseases. Its products include pathogen inspection solutions such as respiratory, gastrointestinal, tuberculosis and meningitis pathogens.

SEEGENE (XKRX:096530) Headlines

No Headlines